Free Trial
NASDAQ:ENTX

Entera Bio (ENTX) Stock Price, News & Analysis

Entera Bio logo
$1.82 +0.02 (+1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$1.84 +0.02 (+0.88%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Entera Bio Stock (NASDAQ:ENTX)

Key Stats

Today's Range
$1.76
$1.89
50-Day Range
$1.73
$2.13
52-Week Range
$1.50
$2.79
Volume
114,210 shs
Average Volume
105,084 shs
Market Capitalization
$82.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Entera Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

ENTX MarketRank™: 

Entera Bio scored higher than 39% of companies evaluated by MarketBeat, and ranked 690th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Entera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Entera Bio has received no research coverage in the past 90 days.

  • Read more about Entera Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Entera Bio are expected to decrease in the coming year, from ($0.28) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Entera Bio is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Entera Bio is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Entera Bio has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Entera Bio's valuation and earnings.
  • Percentage of Shares Shorted

    0.08% of the outstanding shares of Entera Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entera Bio has recently decreased by 32.37%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Entera Bio does not currently pay a dividend.

  • Dividend Growth

    Entera Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.08% of the outstanding shares of Entera Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entera Bio has recently decreased by 32.37%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for ENTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Entera Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.38% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 14.11% of the stock of Entera Bio is held by institutions.

  • Read more about Entera Bio's insider trading history.
Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

ENTX Stock Analysis - Frequently Asked Questions

Entera Bio's stock was trading at $2.12 on January 1st, 2025. Since then, ENTX stock has decreased by 13.2% and is now trading at $1.84.

Entera Bio Ltd. (NASDAQ:ENTX) posted its earnings results on Friday, May, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $0.04 million for the quarter. Entera Bio had a negative trailing twelve-month return on equity of 95.10% and a negative net margin of 4,525.11%.

Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.

Entera Bio's top institutional investors include Bessemer Group Inc. (0.31%). Insiders that own company stock include Miranda Jayne Toledano, Sean Ellis and Haya Taitel.
View institutional ownership trends
.

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

Company Calendar

Last Earnings
5/09/2025
Today
8/08/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTX
CIK
1638097
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$10.00
Potential Upside/Downside
+440.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.54 million
Net Margins
-4,525.11%
Pretax Margin
-4,518.83%
Return on Equity
-95.10%
Return on Assets
-82.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.07
Quick Ratio
13.07

Sales & Book Value

Annual Sales
$180 thousand
Price / Sales
467.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
8.04

Miscellaneous

Outstanding Shares
45,450,000
Free Float
40,734,000
Market Cap
$84.08 million
Optionable
Optionable
Beta
1.52

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ENTX) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners